Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.
about
Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionCultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic modelSelection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelA novel approach for assessing the susceptibility of Escherichia coli to antibiotics.Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.Development of an Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Amoxicillin in Broth Medium and its Application to an In Vitro Pharmacokinetic and Pharmacodynamic Model.Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center
P2860
Q33797936-205F4944-0C44-4868-8CBD-9D3E78F32BA6Q34042257-30B8D398-36EC-46C1-A340-6B58C54FAC46Q34737629-91334652-4893-4FF6-8ED7-13D527775005Q34820573-AAE32F27-EDB5-4EAF-92D3-6405EF5716B2Q35165999-7C33E00A-4B74-42C7-90B3-66EF09EE1EA1Q35635652-2E2FEE8B-7C6B-4E90-BF4D-67FBCAAE0031Q36242447-D212F840-4F1C-489D-815F-5696F4F6B728Q37568933-E65CACAA-720D-4549-A665-546953D7B950Q37607163-939B6C5D-315A-4DD7-9ECE-D55D8B438591Q38626980-B3C7E873-D4B8-48CC-BC72-E46C99D31222Q38880229-8E1FDE1A-7647-4D51-AD19-5A800993B6E6Q40666822-F0583F81-FCB0-4E7C-B011-B26754BFEE1DQ42111255-137A3FF6-65BC-4ED5-938F-8DA281A6FDD6Q42627265-2F8A23CC-D61D-4554-AF2C-E5D72058494FQ42838150-5B7625A9-6E46-45C6-AFD5-9A245D5EE749Q51123254-7E3B97D2-2F2C-4C4C-BB7A-B4434781315CQ51714317-E7CA895E-CFD4-4B2D-A78E-77CB503C87D1Q57549024-4C2E5491-15CF-4760-8F31-A2E83A2EF532
P2860
Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@en
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@nl
type
label
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@en
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@en
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@nl
P2093
P2860
P1476
Pharmacokinetic and pharmacody ...... in an in vitro kinetic model.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.9.2436-2440.2001
P407
P577
2001-09-01T00:00:00Z